Use of thiazole derivatives and analogues in the treatment of cancer

Abstract

There is provided a use of a compound of formula (I): wherein X, T, Y5 W, A1, A2, R1, R5 and R6 have meanings given in the description, for the manufacture of a medicament for the treatment of a disorder or condition caused by, linked to, or contributed to by, free fatty acids, such as hyperinsulinemia and associated conditions, including type 2 diabetes and the like.

Description

field of invention [0001] The present invention relates to novel pharmaceutical applications of certain compounds. In particular, the invention relates to the use of such compounds as modulators (eg inhibitors) of free fatty acids (FFAs) and thus in the treatment of hyperinsulinemia and related disorders. Background technique [0002] Elevated FFAs and hyperinsulinemia (excessive secretion of insulin) represent novel targets for the treatment of obesity-related disorders / metabolic syndrome. [0003] Metabolic syndrome is becoming more common and affects approximately 47 million adults in the United States alone. The syndrome is characterized by metabolic risk factors such as central obesity, atherogenic dyslipidemia, hypertension, insulin resistance or glucose intolerance. The syndrome is also characterized by hyperinsulinemia, a prothrombotic state and a proinflammatory state in the blood. [0004] Potential causes of metabolic syndrome include obesity, physiological ina...

AI Technical Summary

Problems solved by technology

Metformin and alpha-glucosidase inhibitors often cause gastrointestinal problems, and PPAR-gamma agonists are prone to weight gain and edema

However, there is no teaching that such thiazolidinones or oxazolidinones are substituted by heterocyclyl, heteroaryl or especially aryl at the 5-position directly or via an alkylene linker, respectively

Images